Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myriad’s Flurizan (correction)

Executive Summary

Flurizan, a selective amyloid lowering agent intended to slow progression of Alzheimer's disease, is currently the only one of its class in Phase III studies. The product's generic name is tarenflurbil, and it is being developed by Myriad Pharmaceuticals; a previous article on Alzheimer's drugs in development misidentified the drug (1"The Pink Sheet" Aug. 13, 2007, p. 10)...

You may also be interested in...

FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting

Drug treatments and biomarker development for Alzheimer's disease are on the agenda of a meeting FDA expects to hold in October with neurology organizations, Janet Woodcock, the agency's chief medical officer, said during a July 25 audio conference sponsored by Avalere

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts